| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f21c1009c60308a64b8e7dc0bb989632 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-31
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K19-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-09
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-755
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-76
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-37 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-755
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-37
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-86
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-10 |
| filingDate |
2009-06-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_36775dae55cd6c1874780b4d673aeb69
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ca5c82c2d1c82968c38e4cd19bc21c08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1e76a3340990a0820d98f1eb5ffac650
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_41b2a917644e7647d953222d7c8c6b57
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e53bd74d8d74d721c11a8ba5a27949c9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d5f3186aabda571cc88e21228823e8d1 |
| publicationDate |
2009-12-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CA-2728012-A1 |
| titleOfInvention |
Factor viii, von willebrand factor or complexes thereof with prolonged in vivo half-life |
| abstract |
The present invention relates to modified nucleic acid sequences coding for coagulation factor VIII (FVIII) and for von Willebrand factor (VWF) as well as complexes thereof and their derivatives, recombinant expression vectors containing such nucleic acid sequences, host cells transformed with such recombinant expression vectors, recombinant polypeptides and derivatives coded for by said nucleic acid sequences which recombinant polypeptides and derivatives do have biological activities together with prolonged in vivo half-life and/or improved in vivo recovery compared to the unmodified wild-type protein. The invention also relates to corresponding FVIII sequences that result in improved expression yield. The present invention further relates to processes for the manufacture of such recombinant proteins and their derivatives. The invention also relates to a transfer vector for use in human gene therapy, which comprises such modified nucleic acid sequences. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11370827-B2 |
| priorityDate |
2008-06-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |